Unicycive Therapeutics (UNCY) Cash from Financing Activities (2020 - 2026)

Unicycive Therapeutics (UNCY) has 6 years of Cash from Financing Activities data on file, last reported at $19.6 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 668.62% year-over-year to $19.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $63.5 million (up 3167.68% YoY) and the FY2025 annual result came in at $46.5 million, up 3.06% from the prior year.
• Cash from Financing Activities rose to $19.6 million in Q1 2026, from $6.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $45.7 million in Q1 2024 to a low of -$811000.0 in Q2 2024.
• A 4-year average of $11.6 million and a median of $4.6 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 207.84% — and 2025, when it soared 16871.97%.
• Tracing UNCY's Cash from Financing Activities over 4 years: stood at -$205000.0 in 2023, then jumped by 278.05% to $365000.0 in 2024, then jumped by 1709.86% to $6.6 million in 2025, then surged by 196.23% to $19.6 million in 2026.
• The last three Cash from Financing Activities figures came in at $19.6 million (Q1 2026), $6.6 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.